Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2016-03-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/910 |
| _version_ | 1828481552925851648 |
|---|---|
| author | Arpita Desai Smitha P. Menon Grace K. Dy |
| author_facet | Arpita Desai Smitha P. Menon Grace K. Dy |
| author_sort | Arpita Desai |
| collection | DOAJ |
| description | During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway. |
| first_indexed | 2024-12-11T07:58:41Z |
| format | Article |
| id | doaj.art-d09a5e7041374abfad9cf1d1e7f7bc42 |
| institution | Directory Open Access Journal |
| issn | 2095-3941 2095-3941 |
| language | English |
| last_indexed | 2024-12-11T07:58:41Z |
| publishDate | 2016-03-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-d09a5e7041374abfad9cf1d1e7f7bc422022-12-22T01:15:11ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412016-03-01131778610.20892/j.issn.2095-3941.2016.00082016000008Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment optionsArpita Desai0Smitha P. Menon1Grace K. Dy2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226-0509, USADepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA;During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.http://www.cancerbiomed.org/index.php/cocr/article/view/910RASRAFMEKreceptor tyrosine kinases (RTK)fibroblast growth factor receptor (FGFR)non-small cell lung cance (NSCLC) |
| spellingShingle | Arpita Desai Smitha P. Menon Grace K. Dy Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options Cancer Biology & Medicine RAS RAF MEK receptor tyrosine kinases (RTK) fibroblast growth factor receptor (FGFR) non-small cell lung cance (NSCLC) |
| title | Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options |
| title_full | Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options |
| title_fullStr | Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options |
| title_full_unstemmed | Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options |
| title_short | Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options |
| title_sort | alterations in genes other than i egfr alk ros1 i in non small cell lung cancer trials and treatment options |
| topic | RAS RAF MEK receptor tyrosine kinases (RTK) fibroblast growth factor receptor (FGFR) non-small cell lung cance (NSCLC) |
| url | http://www.cancerbiomed.org/index.php/cocr/article/view/910 |
| work_keys_str_mv | AT arpitadesai alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions AT smithapmenon alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions AT gracekdy alterationsingenesotherthaniegfralkros1iinnonsmallcelllungcancertrialsandtreatmentoptions |